The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process

BACKGROUND AND OBJECTIVE: Fabry disease, an X-linked lysosomal storage disorder characterized by absent or reduced alpha-galactosidase activity, is a lifelong disease that impairs patients’ quality of life. Patients with Fabry disease have a considerably shortened lifespan, with mortality being main...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aneal, Sirrs, Sandra M., Bichet, Daniel G., Morel, Chantal F., Tocoian, Adina, Lan, Lan, West, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602602/
https://www.ncbi.nlm.nih.gov/pubmed/34542871
http://dx.doi.org/10.1007/s40268-021-00361-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602602/
https://www.ncbi.nlm.nih.gov/pubmed/34542871
http://dx.doi.org/10.1007/s40268-021-00361-4

Ejemplares similares